Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + bemipalimab vs toripalimab + chemotherapy in first-line ESCC with specific mutations
ChiCTR2600129030Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Toripalimab plus chemotherapy with Anlotinib plus bemipalimab (2 arms). Primary endpoints: Overall survival and Investigator-assessed progression-free survival (PFS). Started Jul 2026; status: recruiting.
02
Drugs
anlotinibbemipalimabtoripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600129030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129030.